Category: Frequency Therapeutics

WOBURN, MASSACHUSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, announced this week that it has agreed to sell 2,350,108 shares of its common stock in a private placement to institutional and accredited investors.…

WOBURN, MASSACHUSETTS — Frequency Therapeutics, Inc., announced top-line data from an exploratory clinical study designed to show whether drug levels of FX-322 in the cochlea can be directly measured. In addition to confirming the viability of the approach, study results showed measurable concentrations of FX-322 in every patient and that anatomical factors did not prevent…

WOBURN, MASSACHUSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has announced business updates and financial results for the third quarter ending September 30, 2019. “This has been a tremendously productive period for…

WOBURN, MASSACHUSETTS — Biotech startup Frequency Therapeutics today announced that dosing has commenced in a Phase 2a clinical study of FX-322, a locally administered investigational drug candidate designed to regenerate auditory hair cells and restore hearing function. The objectives of the Phase 2a study are to further establish the positive hearing signal observed in Frequency’s…

WOBURN, MASSACHUSSETTS — Biotech startup Frequency Therapeutics announced the pricing of its initial public offering (IPO) at approximately $84 million. The company is planning to use funds raised by the IPO to complete the Phase 2a trial of FX-322, a regenerative therapeutic for the treatment of sensorineural hearing loss and also to advance discovery programs…

WOBURN, MASSACHUSSETTS — Biotech startup Frequency Therapeutics has set a preliminary $100 million IPO target, according to paperwork filed with the US Securities Exchange Commission (SEC) on Friday. The company has applied for a Nasdaq listing under the stock symbol ‘FREQ’. Frequency plans to use the money raised by the IPO to complete the Phase…

TOKYO, JAPAN and WOBURN, MASSACHUSETTS — Astellas Pharma and Frequency Therapeutics today announced that they have entered into an exclusive license agreement to develop and commercialize Frequency’s regenerative therapeutic candidate, FX-322, for the treatment of sensorineural hearing loss, the most common type of hearing loss.  Under the terms of the agreement, Astellas will be responsible…